HBL
MCID: HPT022
MIFTS: 56

Hepatoblastoma (HBL)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatoblastoma

MalaCards integrated aliases for Hepatoblastoma:

Name: Hepatoblastoma 12 77 54 38 30 56 6 45 15 17 74
Hbl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:687
KEGG 38 H02302
MeSH 45 D018197
NCIt 51 C3728
SNOMED-CT 69 45024009
ICD10 34 C22.2
UMLS 74 C0206624

Summaries for Hepatoblastoma

NIH Rare Diseases : 54 Hepatoblastoma is a rare malignant (cancerous) tumor of the liver that usually occurs in the first 3 years of life. In early stages of the condition, there may be no concerning signs or symptoms. As the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. The exact underlying cause of hepatoblastoma is poorly understood. Risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis B infection, biliary atresia, and several different genetic conditions (i.e. Beckwith-Wiedemann syndrome, familial adenomatous polyposis, Aicardi syndrome, Glycogen storage disease, and Simpson-Golabi-Behmel syndrome). Treatment varies based on the severity of the condition but may include a combination of surgery, watchful waiting, chemotherapy, and/or radiation therapy.

MalaCards based summary : Hepatoblastoma, also known as hbl, is related to beckwith-wiedemann syndrome and hepatocellular carcinoma, and has symptoms including icterus An important gene associated with Hepatoblastoma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Wnt signaling pathway and PI3K-Akt signaling pathway. The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include liver, fetal liver and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Hepatoblastoma is an uncommon malignant liver cancer occurring in infants and children and composed of... more...

Related Diseases for Hepatoblastoma

Diseases related to Hepatoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 beckwith-wiedemann syndrome 32.1 AFP CDKN1C GPC3 H19 IGF2 TP53
2 hepatocellular carcinoma 31.4 AFP APC BIRC5 CASP3 CRNDE CTNNB1
3 familial adenomatous polyposis 31.0 APC CTNNB1 TP53
4 embryonal sarcoma 30.4 CTNNB1 GPC3 TP53
5 teratoma 30.4 AFP KRT7 TP53
6 familial adenomatous polyposis 1 30.2 APC CTNNB1
7 adenocarcinoma 30.1 APC BIRC5 CTNNB1 H19 TP53
8 adenoma 30.0 APC CTNNB1 PLAG1 TP53
9 hemihyperplasia, isolated 29.8 CDKN1C H19 IGF2
10 intrahepatic cholangiocarcinoma 29.4 AFP CTNNB1 KRT7 TP53 TUG1
11 cholangiocarcinoma 29.0 AFP CTNNB1 GPC3 H19 HGF KRT7
12 lung cancer susceptibility 3 28.2 APC BIRC5 CASP3 CTNNB1 CYCS H19
13 breast cancer 28.1 APC BIRC5 CASP3 CRNDE CTNNB1 CYCS
14 mixed hepatoblastoma 12.3
15 macrotrabecular hepatoblastoma 12.1
16 hypobetalipoproteinemia, familial, 2 11.4
17 chylomicron retention disease 11.1
18 desmoid disease, hereditary 10.5 APC CTNNB1
19 silver-russell syndrome due to an imprinting defect of 11p15 10.5 H19 IGF2
20 silver-russell syndrome due to 11p15 microduplication 10.5 H19 IGF2
21 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
22 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.5 H19 IGF2
23 hepatitis 10.4
24 intestinal benign neoplasm 10.4 APC CTNNB1 TP53
25 short-rib thoracic dysplasia 4 with or without polydactyly 10.4 CASP3 TP53
26 peutz-jeghers syndrome 10.4 APC CTNNB1 TP53
27 colorectal adenoma 10.4 APC CTNNB1 TP53
28 atypical teratoid rhabdoid tumor 10.4 CTNNB1 IGF2 TP53
29 pharynx cancer 10.4 CASP3 CTNNB1 TP53
30 embryoma 10.4 AFP GPC3 IGF2
31 testicular malignant germ cell cancer 10.4 AFP GPC3
32 nasopharyngeal disease 10.4 CASP3 CTNNB1 TP53
33 cervix disease 10.3 CASP3 CTNNB1 TP53
34 hepatitis b 10.3
35 hyperplastic polyposis syndrome 10.3 APC TP53
36 male reproductive organ cancer 10.3 CASP3 CTNNB1 TP53
37 colonic disease 10.3 CASP3 CTNNB1 TP53
38 tongue cancer 10.3 CASP3 CTNNB1 TP53
39 stomach disease 10.3 CASP3 CTNNB1 TP53
40 female reproductive system disease 10.3 CASP3 CTNNB1 TP53
41 reproductive system disease 10.3 CASP3 CTNNB1 TP53
42 respiratory system cancer 10.3 CASP3 CTNNB1 TP53
43 testicular germ cell tumor 10.3 AFP GPC3 TP53
44 germ cell cancer 10.3 AFP H19 IGF2
45 intrahepatic bile duct adenoma 10.3 AFP KRT7
46 hepatic adenomas, familial 10.3 AFP APC CTNNB1 GPC3
47 uterine anomalies 10.3 AFP CASP3 CTNNB1 TP53
48 intestinal disease 10.3 CASP3 CTNNB1 TP53
49 ovarian embryonal carcinoma 10.3 AFP GPC3
50 meninges sarcoma 10.3 IGF2 TP53

Graphical network of the top 20 diseases related to Hepatoblastoma:



Diseases related to Hepatoblastoma

Symptoms & Phenotypes for Hepatoblastoma

UMLS symptoms related to Hepatoblastoma:


icterus

GenomeRNAi Phenotypes related to Hepatoblastoma according to GeneCards Suite gene sharing:

27 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.98 CTNNB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.98 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.98 AFP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.98 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.98 AFP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.98 IGF2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.98 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.98 KRT7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.98 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.98 IGF2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.98 APC CTNNB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.98 AFP APC KRT7
13 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.98 IGF2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.98 CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.98 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.98 AFP APC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.98 CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.98 APC CTNNB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.98 AFP IGF2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.98 AFP
21 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.98 CTNNB1 IGF2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.98 CTNNB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.98 APC KRT7 CTNNB1 IGF2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.98 CTNNB1 IGF2

MGI Mouse Phenotypes related to Hepatoblastoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 APC APOA1 BIRC5 CASP3 CTNNB1 CYCS
2 cardiovascular system MP:0005385 10.24 APC APOA1 CASP3 CDO1 CTNNB1 CYCS
3 homeostasis/metabolism MP:0005376 10.15 AFP APC APOA1 BIRC5 CASP3 CDO1
4 endocrine/exocrine gland MP:0005379 10.14 AFP APC APOA1 BIRC5 CASP3 CDO1
5 embryo MP:0005380 10.09 APC BIRC5 CTNNB1 CYCS GPC3 HGF
6 craniofacial MP:0005382 10.06 APC CASP3 CDO1 CTNNB1 CYCS GPC3
7 integument MP:0010771 9.92 APC APOA1 CASP3 CTNNB1 GPC3 IGF2
8 liver/biliary system MP:0005370 9.86 AFP APC APOA1 CTNNB1 HGF IGF2
9 pigmentation MP:0001186 9.55 APC CASP3 CTNNB1 GPC3 TP53
10 renal/urinary system MP:0005367 9.5 APC CASP3 CTNNB1 GPC3 IGF2 KRT7
11 reproductive system MP:0005389 9.28 AFP APC CASP3 CDO1 CTNNB1 GPC3

Drugs & Therapeutics for Hepatoblastoma

Drugs for Hepatoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 1,Not Applicable 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Sargramostim Approved, Investigational Phase 4,Phase 1,Not Applicable 123774-72-1, 83869-56-1
4 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Adjuvants, Immunologic Phase 4,Phase 1,Not Applicable
6
Cisplatin Approved Phase 3,Phase 2 15663-27-1 441203 84093 2767
7
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
8
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
9
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
10
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
11
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
12
Amifostine Approved, Investigational Phase 3,Phase 1 20537-88-6 2141
13
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
14
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3 61825-94-3 6857599 5310940 9887054 43805
15
Sorafenib Approved, Investigational Phase 2, Phase 3,Phase 3 284461-73-0 216239 406563
16
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
17
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
18
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177 70789204
19
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
20
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
21
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
22
Sevoflurane Approved, Vet_approved Phase 2, Phase 3 28523-86-6 5206
23
Rocuronium Approved Phase 2, Phase 3 119302-91-9, 143558-00-3 441290
24
Cyproheptadine Approved Phase 3 129-03-3 2913
25
Histamine Approved, Investigational Phase 3 51-45-6 774
26
Doxil Approved June 1999 Phase 3,Phase 2 31703
27
Camptothecin Experimental Phase 3 7689-03-4
28 Liver Extracts Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
33 topoisomerase I inhibitors Phase 2, Phase 3,Phase 3,Phase 1
34 Etoposide phosphate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
35 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
36 Radiation-Protective Agents Phase 3,Phase 1
37 Protective Agents Phase 3,Phase 1,Not Applicable
38 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
39 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
40 Antimetabolites Phase 3,Phase 2,Phase 1
41 Antioxidants Phase 3
42 Antidotes Phase 3
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1
44 Chelating Agents Phase 3
45 Antitubercular Agents Phase 3
46 sodium thiosulfate Phase 3
47 Keratolytic Agents Phase 2, Phase 3
48 Podophyllotoxin Phase 2, Phase 3 518-28-5
49 Dermatologic Agents Phase 2, Phase 3,Phase 3
50 Antiviral Agents Phase 2, Phase 3,Phase 3,Phase 1

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
2 Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer Completed NCT00003994 Phase 3 cisplatin;vincristine sulfate;fluorouracil;amifostine trihydrate;carboplatin
3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
4 Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer Completed NCT00652132 Phase 3 cisplatin;sodium thiosulfate
5 Chemotherapy in Treating Children With Liver Cancer Completed NCT00003912 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride
6 Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Recruiting NCT03533582 Phase 2, Phase 3 Carboplatin;Cisplatin;Doxorubicin;Etoposide;Fluorouracil;Gemcitabine;Irinotecan;Oxaliplatin;Sorafenib;Vincristine Sulfate
7 Paediatric Hepatic International Tumour Trial Recruiting NCT03017326 Phase 3 Cisplatin;Doxorubicin;Carboplatin;5Fluorouracil;Vincristine;Etoposide;Irinotecan;Gemcitabine;Oxaliplatin;Sorafenib
8 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Active, not recruiting NCT00980460 Phase 3 Cisplatin;Dexrazoxane;Doxorubicin Hydrochloride;Fluorouracil;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
9 the Efficacy and Safety of Sugammadex in Children 0-2 Years Old Not yet recruiting NCT03728543 Phase 2, Phase 3 Sugammadex
10 To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
11 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
12 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Unknown status NCT00287976 Phase 2 irinotecan hydrochloride
13 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Unknown status NCT00077389 Phase 2 carboplatin;cisplatin;doxorubicin hydrochloride
14 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
15 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
16 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
17 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
18 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
19 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
20 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting NCT01956669 Phase 2 Pazopanib GW786034
21 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
22 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03526250 Phase 2 Palbociclib
23 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03698994 Phase 2 Ulixertinib
24 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
25 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03220035 Phase 2 Vemurafenib
26 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03233204 Phase 2 Olaparib
27 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib
28 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
29 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
30 Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Recruiting NCT01804634 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Sirolimus
31 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Suspended NCT03213665 Phase 2 Tazemetostat
32 Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2 Imetelstat Sodium
33 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Completed NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
34 EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT03618381 Phase 1
35 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
36 A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy Recruiting NCT02085148 Phase 1 Regorafenib (BAY73-4506);Vincristine (Cellcristin®);Irinotecan (Irinotecan Cell pharm®)
37 Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors Recruiting NCT03507491 Phase 1 Gemcitabine;Nab-paclitaxel
38 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1 sirolimus
39 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1 amifostine trihydrate;busulfan;filgrastim;melphalan;thiotepa
40 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
41 Cancer and Hearing Loss Related in Children Unknown status NCT02425397
42 Biomarkers in Tissue Samples From Young Patients With Liver Cancer Completed NCT01336881
43 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755
44 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer Completed NCT01353300
45 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
46 Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience Recruiting NCT02557750
47 Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Recruiting NCT01505569 Not Applicable Ifosfamide;Etoposide;Mesna;Busulfan;Melphalan;Thiotepa;Carboplatin;Paclitaxel;Anti-seizure prophylaxis;Ursodiol
48 Diagnostic Accuracy of PIVKA-II Combining With Alpha-Fetoprotein in Hepatic Tumor Not yet recruiting NCT03645655
49 Hepatoblastoma Biology Study and Tissue Bank Withdrawn NCT00228683 Not Applicable
50 Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors Withdrawn NCT00624962 Not Applicable

Search NIH Clinical Center for Hepatoblastoma

Cochrane evidence based reviews: hepatoblastoma

Genetic Tests for Hepatoblastoma

Genetic tests related to Hepatoblastoma:

# Genetic test Affiliating Genes
1 Hepatoblastoma 30

Anatomical Context for Hepatoblastoma

MalaCards organs/tissues related to Hepatoblastoma:

42
Liver, Fetal Liver, Lung, Kidney, Testes, Brain, Myeloid

Publications for Hepatoblastoma

Articles related to Hepatoblastoma:

(show top 50) (show all 1452)
# Title Authors Year
1
Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome. ( 30270492 )
2019
2
Hepatoblastoma and Wilms' tumour in an infant with Beckwith-Wiedemann syndrome and diazoxide resistant congenital hyperinsulinism. ( 30817313 )
2019
3
Hepatoblastoma Mimicking Hemangioma in Labeled Red Blood Cell Scintigraphy. ( 30624263 )
2019
4
Hepatitis C virus nonstructural 5A protein inhibits the starvation‑induced apoptosis of hepatoblastoma cells by increasing Beclin 1 expression. ( 30896822 )
2019
5
Congenital hepatoblastoma in a growing health economy. ( 30898949 )
2019
6
Mechanisms of Anticancer Drug Resistance in Hepatoblastoma. ( 30909445 )
2019
7
The Role of MicroRNAs in Hepatoblastoma Tumors. ( 30909459 )
2019
8
Prognostic Factors for Liver Transplantation in Unresectable Hepatoblastoma. ( 30086577 )
2019
9
Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. ( 30160353 )
2019
10
Results of surgical resections with positive margins for children with hepatoblastoma: Case series from a single Asian center. ( 30255649 )
2019
11
Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong. ( 30270490 )
2019
12
Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferation. ( 30320362 )
2019
13
Reiterative Radiofrequency Ablation in the Management of Pediatric Patients with Hepatoblastoma Metastases to the Lung, Liver, or Bone. ( 30350173 )
2019
14
Inhibition of autophagy enhances adenosine‑induced apoptosis in human hepatoblastoma HepG2 cells. ( 30535464 )
2019
15
Longitudinal Monitoring of Alpha-Fetoprotein by Dried Blood Spot for Hepatoblastoma Screening in Beckwith⁻Wiedemann Syndrome. ( 30646549 )
2019
16
JTC-801 inhibits the proliferation and metastasis of the Hep G2 hepatoblastoma cell line by regulating the phosphatidylinositol 3-kinase/protein kinase B signalling pathway. ( 30675258 )
2019
17
Hepatoblastoma with Precocious Puberty. ( 30686892 )
2019
18
Indications and efficacy of conversion from tacrolimus- to sirolimus-based immunosuppression in pediatric patients who underwent liver transplantation for unresectable hepatoblastoma. ( 30719825 )
2019
19
Contemporary management of hepatoblastoma. ( 30762666 )
2019
20
Navigation surgery using indocyanine green fluorescent imaging for hepatoblastoma patients. ( 30778701 )
2019
21
TEA domain transcription factor 4 (TEAD4) is the major mediator of Yap oncogenic activity in mouse and human hepatoblastoma. ( 30794805 )
2019
22
β-Catenin and yes-associated protein 1 cooperate in hepatoblastoma pathogenesis. ( 30794807 )
2019
23
Surgical and anesthetic management for hepatectomy in two pediatric patients with trisomy 18, pulmonary hypertension, and hepatoblastoma. ( 30803146 )
2019
24
CircHMGCS1 Promotes Hepatoblastoma Cell Proliferation by Regulating the IGF Signaling Pathway and Glutaminolysis. ( 30809316 )
2019
25
Multifocal hepatoblastoma: What is the risk of recurrent disease in the remnant liver? ( 30819543 )
2019
26
mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development. ( 30863496 )
2019
27
Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells. ( 30864675 )
2019
28
Pure fetal hepatoblastoma in a young female. ( 30881978 )
2019
29
Arctigenin induces apoptosis in human hepatoblastoma cells. ( 30891641 )
2019
30
The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival. ( 30898394 )
2019
31
Prognostic and therapeutic factors influencing the clinical outcome of hepatoblastoma after liver transplantation: A single-institute experience. ( 29341393 )
2018
32
Two Cases of Hepatoblastoma in Young Adults. ( 29412770 )
2018
33
Long-term outcomes of liver transplantation for hepatoblastoma: A single-center 14-year experience. ( 29888545 )
2018
34
A novel tissue-based A9-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors. ( 29446530 )
2018
35
Pediatric hepatoblastoma and hepatocellular carcinoma: lessons learned in the last decade. ( 29383417 )
2018
36
Oridonin increases anticancer effects of lentinan in HepG2 human hepatoblastoma cells. ( 29434900 )
2018
37
Pediatric patient with end-stage kidney disease secondary to Eagle-Barrett syndrome and metastatic unresectable hepatoblastoma treated successfully with chemotherapy and liver-kidney transplant. ( 29356335 )
2018
38
20(S)-Protopanaxadiol induces apoptosis in human hepatoblastoma HepG2 cells by downregulating the protein kinase B signaling pathway. ( 29434714 )
2018
39
Hepatoblastoma in a child with dextrocardia and possible histopathological alteration reminiscent of hepatocellular carcinoma after neoadjuvant chemotherapy. ( 29881566 )
2018
40
Hepatoblastoma: current understanding, recent advances, and controversies. ( 29375822 )
2018
41
Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. ( 29755772 )
2018
42
Comprehensive analysis and experimental verification of LINC01314 as a tumor suppressor in hepatoblastoma. ( 29571247 )
2018
43
Metastasectomy of Hepatoblastoma Utilizing a Novel Overlay Fluorescence Imaging System. ( 29906233 )
2018
44
Chrysotoxene induces apoptosis of human hepatoblastoma HepG2 cells <i>in vitro</i> and <i>in vivo</i> via activation of the mitochondria-mediated apoptotic signaling pathway. ( 29541233 )
2018
45
Single-walled carbon nanohorn aggregates promotes mitochondrial dysfunction-induced apoptosis in hepatoblastoma cells by targeting SIRT3. ( 29956732 )
2018
46
Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma. ( 29414822 )
2018
47
Hepatoblastoma in a Child With Early-onset Cirrhosis. ( 29420370 )
2018
48
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. ( 29922990 )
2018
49
MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance. ( 29889802 )
2018
50
Right trisegmentectomy after portal vein embolization in a high-risk toddler with hepatoblastoma. ( 29600326 )
2018

Variations for Hepatoblastoma

ClinVar genetic disease variations for Hepatoblastoma:

6 (show all 26)
# Gene Variation Type Significance SNP ID Assembly Location
1 RAF1 NM_002880.3(RAF1): c.226A> G (p.Met76Val) single nucleotide variant Uncertain significance rs730880999 GRCh37 Chromosome 3, 12653543: 12653543
2 RAF1 NM_002880.3(RAF1): c.226A> G (p.Met76Val) single nucleotide variant Uncertain significance rs730880999 GRCh38 Chromosome 3, 12612044: 12612044
3 STK11 NM_000455.4(STK11): c.397G> A (p.Val133Met) single nucleotide variant Uncertain significance rs567769257 GRCh38 Chromosome 19, 1219346: 1219346
4 STK11 NM_000455.4(STK11): c.397G> A (p.Val133Met) single nucleotide variant Uncertain significance rs567769257 GRCh37 Chromosome 19, 1219345: 1219345
5 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh37 Chromosome 5, 112175474: 112175474
6 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh38 Chromosome 5, 112839777: 112839777
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
9 CTNNB1 NM_001904.3(CTNNB1): c.121A> G (p.Thr41Ala) single nucleotide variant Conflicting interpretations of pathogenicity, other rs121913412 GRCh37 Chromosome 3, 41266124: 41266124
10 CTNNB1 NM_001904.3(CTNNB1): c.121A> G (p.Thr41Ala) single nucleotide variant Conflicting interpretations of pathogenicity, other rs121913412 GRCh38 Chromosome 3, 41224633: 41224633
11 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
12 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh38 Chromosome 3, 41224606: 41224606
13 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
14 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh38 Chromosome 3, 41224613: 41224613
15 CDK4 NM_000075.3(CDK4): c.625C> T (p.Arg209Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs140644696 GRCh37 Chromosome 12, 58144446: 58144446
16 CDK4 NM_000075.3(CDK4): c.625C> T (p.Arg209Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs140644696 GRCh38 Chromosome 12, 57750663: 57750663
17 MSH6 NM_000179.2(MSH6): c.942C> G (p.Ser314Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs150440246 GRCh37 Chromosome 2, 48026064: 48026064
18 MSH6 NM_000179.2(MSH6): c.942C> G (p.Ser314Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs150440246 GRCh38 Chromosome 2, 47798925: 47798925
19 PTCH1 NM_000264.4(PTCH1): c.2270T> C (p.Phe757Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs547954117 GRCh37 Chromosome 9, 98229688: 98229688
20 PTCH1 NM_000264.4(PTCH1): c.2270T> C (p.Phe757Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs547954117 GRCh38 Chromosome 9, 95467406: 95467406
21 CTNNB1 NM_001904.3(CTNNB1): c.84_95delGTCTTACCTGGA (p.Gln28_Asp32delinsHis) deletion other rs1553630102 GRCh38 Chromosome 3, 41224596: 41224607
22 CTNNB1 NM_001904.3(CTNNB1): c.84_95delGTCTTACCTGGA (p.Gln28_Asp32delinsHis) deletion other rs1553630102 GRCh37 Chromosome 3, 41266087: 41266098
23 MN1 NM_002430.2(MN1): c.927_929delGCA (p.Gln309del) deletion other rs747503495 GRCh38 Chromosome 22, 27799615: 27799617
24 MN1 NM_002430.2(MN1): c.927_929delGCA (p.Gln309del) deletion other rs747503495 GRCh37 Chromosome 22, 28195603: 28195605
25 ARID1A NM_006015.5(ARID1A): c.6259G> A (p.Gly2087Arg) single nucleotide variant other rs1553153748 GRCh37 Chromosome 1, 27106648: 27106648
26 ARID1A NM_006015.5(ARID1A): c.6259G> A (p.Gly2087Arg) single nucleotide variant other rs1553153748 GRCh38 Chromosome 1, 26780157: 26780157

Copy number variations for Hepatoblastoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48501 11 1 52900000 Methylation H19 Hepatoblastoma
2 48504 11 1 52900000 Methylation IGF2 Hepatoblastoma

Expression for Hepatoblastoma

Search GEO for disease gene expression data for Hepatoblastoma.

Pathways for Hepatoblastoma

Pathways related to Hepatoblastoma according to KEGG:

38
# Name Kegg Source Accession
1 Wnt signaling pathway hsa04310

Pathways related to Hepatoblastoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 APC CASP3 CTNNB1 HGF IGF2 TP53
2
Show member pathways
12.67 BIRC5 CASP3 CYCS IGF2 TP53
3
Show member pathways
12.66 APC BIRC5 CASP3 CTNNB1 CYCS TP53
4
Show member pathways
12.62 APC CTNNB1 HGF IGF2 TP53
5
Show member pathways
12.43 APC CASP3 CTNNB1 CYCS HGF TP53
6 12.3 APC BIRC5 CTNNB1 TP53
7
Show member pathways
12.27 APC CTNNB1 GPC3 TP53
8 11.98 AFP APC BIRC5 CTNNB1
9 11.95 APC BIRC5 CASP3 CTNNB1 CYCS HGF
10 11.88 AFP APC HGF TP53
11 11.77 APC BIRC5 CASP3 CTNNB1 TP53
12 11.74 CASP3 CYCS TP53
13 11.74 CASP3 CTNNB1 GPC3 HGF IGF2 TP53
14 11.71 APC CTNNB1 IGF2 TP53
15
Show member pathways
11.68 BIRC5 CASP3 CYCS
16
Show member pathways
11.54 CASP3 CYCS TP53
17 11.43 APC CASP3 TP53
18 11.42 BIRC5 CASP3 CYCS TP53
19 11.39 BIRC5 CASP3 TP53
20 11.17 CASP3 CYCS TP53
21 11.06 APC CTNNB1 HGF

GO Terms for Hepatoblastoma

Cellular components related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-catenin destruction complex GO:0030877 8.96 APC CTNNB1
2 Wnt signalosome GO:1990909 8.62 APC CTNNB1

Biological processes related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 BIRC5 CASP3 CTNNB1 HGF TP53
2 cytokine-mediated signaling pathway GO:0019221 9.73 BIRC5 CASP3 HGF TP53
3 negative regulation of transcription, DNA-templated GO:0045892 9.72 BIRC5 CDKN1C CTNNB1 PPARA TP53
4 negative regulation of inflammatory response GO:0050728 9.65 APOA1 HGF PPARA
5 cellular protein metabolic process GO:0044267 9.46 AFP APOA1 GPC3 IGF2
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 HGF IGF2 TP53
7 anterior/posterior axis specification GO:0009948 9.4 CTNNB1 GPC3
8 striated muscle cell differentiation GO:0051146 9.37 CASP3 IGF2
9 embryonic placenta morphogenesis GO:0060669 8.96 CDKN1C IGF2
10 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 8.8 APC CASP3 CDKN1C

Molecular functions related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CASP3 CDKN1C

Sources for Hepatoblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....